E., Cooper, M
Studies have shown that Ozempic, particularly at higher doses specifically approved for weight management (under the brand Wegovy), often delivers superior results in reducing body weight, BMI, and waist circumference
GLP-1RAs reduce risks of neurocognitive, substance use, cardiovascular and respiratory disorders, but increase risks of gastrointestinal issues, hypotension and pancreatitis
liraglutide significantly decreased body fat and waist-to-hip ratio (p=0.003), and exenatide reduced waist-to-hip ratio but had minimal weight loss benefits.[6] In the STEP1 study, adults with obesity without diabetes receiving semaglutide 2.4mg plus lifestyle interventions had a mean weight loss of 14.9% from baseline in addition to improved fasting glucose and lipids, increased physical activity, and decreased fat mass.[7] The SURMOUNT-1 trial demonstrated that tirzepatide 5mg, 10mg, and 15mg caused significant improvement in weight, total body fat mass, lipids, systolic and diastolic blood pressure, and fasting insulin levels.[5] Cardiovascular disease risk reduction Diabetes represents a major risk factor for cardiovascular disease
(b) from a dual-frame random digit dial (RDD) sample provided by MSG
